The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).

Don’t get me wrong, 50,000,000 is a big number. The story it tells, though, is even bigger. In January, a Kaiser analysis reported on 2023’s finalized ...

A federal commission to examine U.S. chronic disease could undercut real treatment for kids with depression, ADHD and other ...